The innovation grant awarded to Biomensio from the EU Horizon 2020 SME Instrument Phase II in 2019 has significantly boosted the development of our point-of-need diagnostics platform (Grant Agreement number 848986).
Biomensio has continued work on the project as per the project plan. The COVID-19 outbreak in 2020 has pulled Biomensio to test and develop the applicability of our technology also for COVID-19 testing. Driven by the urgency and social importance of developing fast and reliable point-of-need diagnostics for the SARS-Cov-2 and similar viruses, Biomensio have requested to change the project scope for this application. The Commission has on April 18th, 2021 approved our request for this program re-orientation.
A major part of our project continues to focus on the technology platform development, and that work is unaffected by this change. While Biomensio will now be doing the program pilot phase with the COVID-19 test, we will also continue developing our Drugs of Abuse application.